GE Healthcare Showcases Unprecedented 'Win-Win Collaboration' Momentum at the 6th CIIE with Groundbreaking Innovations

Nov 06, 2023 20:57 CST Updated 20:57

GE Healthcare

Digital Solution Provider

Allowing Chinese doctors and patients to enjoy synchronously with the globeGE Healthcare's Latest

Medical Technology.

At the same time, accelerate the promotion of industry-university-research collaboration for win-win cooperation.

Promoting High-Quality Development in China's Healthcare and Wellness Industry.

November 6, 2023, Shanghai

The 6th China International Import Expo (CIIE)

Is becoming a catalyst for the introduction and implementation of innovative achievements

"First Priority"

More cutting-edge technologies and advanced products

Choose to debut or premiere at the CIIE

GE Healthcare, as a global leading medical technology

And Digital Solution Innovators

GE Healthcare has never been absent for six consecutive CIIEs.

Leveraging the CIIE to Showcase Cutting-edge Innovations and Promote Clinical Implementation

Let Chinese doctors and patients and the worldSynchronously enjoy

These latest medical technologies from GE Healthcare

GE Healthcare's Global Executive Vice President and China President & CEO, Tihao Zhang, introduced that since the introduction of the first X-ray machine in China in 1897, GE Healthcare has been deeply rooted in China. Over the course of 45 years of reform and opening up, GE Healthcare has become one of the earliest companies in the medical industry to implement localization in China, with the most achievements. With 1,800 R&D personnel in China, it has three innovation centers and five production bases, establishing a comprehensive medical device R&D and manufacturing capability from basic to high-end. Through original innovations integrating global and Chinese wisdom, industry-university-research-application collaboration, digital-physical integration, and incubation innovations, it achieves "boundaryless innovation," benefiting patients and healthcare providers both in China and globally.

GE Healthcare, as a "full-time participant" of the CIIE for six consecutive years, always holds strategic cooperation signings with upstream and downstream partners as a key highlight of each session. The forward-thinking development concepts and practical approaches of win-win cooperation among all parties merge and interact on GE Healthcare's CIIE booth, becoming a vibrant source of energy driving high-quality development for upstream and downstream partners.

One of the highlights of the collaboration is the official signing of a cooperation agreement between GE Healthcare and New Hope Medical. Based on this strategic agreement, the two parties will engage in long-term cooperation to jointly develop capabilities in healthcare quality management and establish a model center for maternal and child health, promoting the application of innovative diagnostic technologies in non-public healthcare institutions in China.GE Healthcare expressed high anticipation for in-depth cooperation with United Family Healthcare, particularly in the fields of obstetrics, gynecology, breast health, and neonatology. By fully leveraging our clinical application advantages in imaging, we will collaborate with United Family Healthcare to establish demonstration centers for breast/reproductive/obstetric imaging, enhancing the influence of both parties. Such a powerful partnership will undoubtedly bring higher quality, more convenient, and more efficient medical products and services to more patients, improve the accessibility of precision medicine and high-quality medical resources, and contribute to the construction of "Healthy China."

It is reported that this year's CIIEOver 70 companies signed letters of intent and strategic cooperation agreements on the first day.Among numerous signings, one that particularly stands out is the strategic agreement between GE Healthcare and Baxter Healthcare. This strategic collaboration aims to leverage the technical expertise and robust capabilities of both parties in renal care, utilizing advanced ultrasound technology to implement precision medicine, expand the application of ultrasound in the full course management of dialysis, improve treatment outcomes, enhance medical efficiency, and jointly contribute to "Healthy China 2030."

Integration and Connection: GE Healthcare, in response to industry needs, collaborates with industry players and upstream and downstream partners on the grand stage of a new era. United in purpose and working closely together, we remain committed to the mission of treating and saving lives. By channeling the innovative energy of the entire chain, we focus on innovation, further invigorate the win-win cooperation between industry, academia, research, and application, promote high-quality development of dual chains, and advance the shared destiny of humanity.

The all-new Apex Quantum Platform makes its debut in China, representing the latest achievement jointly developed by GE Healthcare's global and Chinese R&D teams. It integrates numerous cutting-edge technologies from GE Healthcare’s decades of expertise in the CT field, featuring a systematic architecture that spans from the hardware platform to the software system, from the reconstruction engine to clinical workflows, bringing revolutionary breakthroughs to clinical CT imaging.

The All-New Apex Quantum Platform: A Remarkable Achievement of GE Healthcare China’s ‘Boundless Innovation’ Strategy

It is reported that the production line for the Apex Quantum Platform equipment is currently being prepared at GE Healthcare's Beijing Imaging Equipment Manufacturing Base. As the new product enters the market, it is expected that the Apex Quantum Platform will accelerate to benefit Chinese doctors and patients, creating boundless healthcare compassion.

GE Healthcare China Unveils SIGNA™ PET/MR Device with "Spectral Therapy System" for the First Time: The Spectral Therapy System, Combined with an Enhanced MR Hardware Platform and TPU Reconstruction System, Achieves Precise Quantification of All Nuclides and Rapid Whole-Body, Full-Sequence Imaging. This Provides Comprehensive Disease State Assessment and More Accurate Treatment Guidance for Various Complex Clinical Conditions Including Neurodegenerative Diseases, Rectal Cancer, Breast Cancer, and Prostate Tumors—Benefiting Patients Worldwide While Accelerating Integrated Tumor Diagnosis and Treatment as Well as Forward-Looking Basic Research.

"Photon Spectrum Diagnosis and Treatment System" Achieves Precise Quantification of All Nuclides, Promoting the Implementation of Innovative Diagnostic and Therapeutic Technologies. GE Healthcare, in collaboration with Stanford University, the University of Wisconsin, and multiple global institutions and installed users, has co-developed a new "Photon Spectrum Diagnosis and Treatment System." By tracking photon energy spectra in real time, it can restore true PET photon information in real time, helping clinicians obtain finer structures, multi-dimensional functional information, and more accurate quantification in a shorter period of time, revealing lesions in a more essential and comprehensive manner.

Since GE Healthcare launched its first integrated PET/MR in 2014, it has continuously promoted the clinical research value and product innovation of this equipment. In recent years, GE Healthcare's R&D team has maintained research collaborations with international university hospitals such as Mayo Clinic, Stanford, and the University of Cambridge. In China, top research-oriented hospitals including Peking Union Medical College Hospital, PLA General Hospital 301, and West China Hospital have been conducting clinical research based on GE Healthcare’s PET/MR platform. GE Healthcare will leverage this industry-academia-research-medical ecosystem, focusing on clinical issues, to carry out projects including academic exchanges, talent development, and research initiatives, continuously advancing the development of nuclear medicine and implementing more innovative technologies in clinical practice to create limitless healthcare compassion.

GE Healthcare Releases for the First Time a Higher Stability and Safety MRI Contrast Agent for Newborns – Gadoterate Meglumine Injection (Trade Name: Clariscan®, applicable for children aged 2 years and below, hereinafter referred to as Clariscan®). Traditional gadolinium-based contrast agents carry potential risks when used in pediatric patients. Represented by Clariscan®, cyclic contrast agents with higher stability and safety have a broader application scope. When used in contrast-enhanced MRI examinations, they can improve the accuracy of imaging tests across all age groups, especially in pediatric imaging examinations. This enables precise screening and early diagnosis and treatment of severe and potentially fatal diseases in children, promoting the implementation of precision medicine in the field of pediatrics.

"Clariscan®" is the second MRI contrast agent launched by GE Healthcare, 23 years after Omniscan® in 1999. Its highly symmetrical structure enhances drug stability: due to its unique structure, this innovative cyclic contrast agent ensures that gadolinium ions are tightly encapsulated at the center of the chelate, effectively preventing the release of gadolinium ions in the body and avoiding exchanges with calcium ions in the body, which could cause biotoxicity. Additionally, Clariscan® has a lower incidence of allergy-like reactions, higher safety, and broader global application, supporting safe and effective contrast-enhanced MRI examinations. Especially for pediatric patients, this high-safety contrast agent can be used for MRI examinations in children aged 2 years and below (including newborns), assisting in qualitative diagnosis and precise evaluation, and providing guidance for subsequent treatment plans. For instance, in the case of neuroblastoma, which is highly prevalent among children, using Clariscan® for contrast-enhanced MRI can accurately display the internal morphology, external boundaries, and blood supply information of tumors, offering a basis for qualitative diagnosis and TNM staging, and guiding subsequent clinical treatment plans. It helps achieve early diagnosis and screening of major diseases in children, promoting the high-quality development of children's healthcare.

GE Healthcare Unveils and Exhibits the Fully Upgraded Invenia™ ABUS 2.0 Automated Breast Ultrasound AI Comprehensive Solution for the First Time. This solution innovatively adopts scan-read separation + AI workstation, which not only enables rapid automatic acquisition of high-quality homogeneous images, improving clinical detection rates, but also achieves remote diagnosis through standardized imaging acquisition and cloud transmission, covering the entire pathway of breast disease screening, diagnosis, and follow-up, promoting large-scale普及screening for breast cancer in extensive grassroots areas across China.

Promote Homogenization of Breast Disease Screening with Standard Acquisition and High-Quality Imaging. The Invenia™ ABUS 2.0 fully automatic breast ultrasound AI comprehensive solution is equipped with GE Healthcare's fifth-generation cSound™ holographic domain imaging platform and features a wide-field arc probe specifically developed for breast ultrasound examinations. While ensuring high-definition uniform images across the entire field and providing an unobstructed view of multiple lesions, it achieves full-breast scanning imaging in just 40 seconds. Additionally, this solution incorporates artificial intelligence (AI)-assisted screening to enhance the detection rate of small lesions, reduce doctors' initial screening time, and meet the needs of precise breast screening at the grassroots level in China, which has a large population base.

Invenia™ ABUS 2.0 Fully Automatic Breast Ultrasound AI Comprehensive Solution can also enable remote connection for image reading and a diagnostic center model, promoting the decentralization of breast cancer screening resources. After front-end clinical scanning, Invenia™ ABUS 2.0 generates standardized, remotely transmittable 3D volumetric ultrasound images, which are transmitted to a remote diagnostic workstation, allowing medical experts to review images remotely and make precise diagnostic decisions. This facilitates the rapid diagnosis, analysis, and archiving of breast diseases, enabling doctors to quickly issue reports or refer patients to higher-level affiliated hospitals for further treatment.

For many years, GE Healthcare has continuously focused on maternal and child health, driving the rapid development of the ultrasound industry with constantly evolving technological breakthroughs and innovative products. At this year's CIIE, GE Healthcare also unveiled for the first time its ultra-high-end research digital mammography system, the Senographe Pristina Hygeia. This mammography system enables full-process tomosynthesis, precise lesion localization, and rapid confirmation of biopsy samples, enhancing the patient experience. By promoting the integration of precision diagnosis and treatment for breast diseases through technological innovation, it provides more comprehensive care for women's health.

GE Healthcare Smart Services Releases Its Latest Achievement in the Field of Digital-Physical Integration — The Equipment Health Intelligent Testing Platform. Unlike traditional equipment health reports that are time-consuming, labor-intensive, and require manual statistics and calculations, the GE Healthcare Equipment Health Intelligent Testing Platform can automatically generate reports with a single click, helping hospitals accurately control the health status of imaging equipment, achieve stable operation of equipment, maximize equipment performance, thereby promoting the efficient integration of clinical practice and equipment, and enhancing doctors' precise diagnosis and treatment capabilities.

AI Intelligent Analysis and Original Factory Expert System Create a Closed Loop for After-Sales Service Quality Control. GE Healthcare has developed an exclusive "Health Check Platform" for medical devices — the Equipment Health Intelligence Measurement Platform. By automatically analyzing and diagnosing data from multiple dimensions of imaging equipment usage such as CT, MR, and ultrasound, the platform generates equipment health reports. Based on the AI-powered intelligent health analysis engine, the entire report generation process in the Intelligence Measurement Platform is highly automated, producing clear and easy-to-understand equipment test reports in a short time while providing modular analysis of the equipment. Through the Equipment Health Intelligence Measurement Platform, hospitals can gain a more objective, comprehensive, and intuitive understanding of the on-site equipment health status, ensuring the clinical effectiveness of imaging equipment. This allows healthy equipment to produce high-quality images, supporting doctors' accurate diagnoses and improving the operational efficiency and management level of hospitals.

GE Healthcare will continue to build a one-stop experience for comprehensive service solutions, helping hospitals use equipment more effectively while enhancing personnel operation and management skills, providing more comprehensive technical support for hospital operations management. In the future, we will continue to strengthen core service experiences and constantly iterate new capabilities in clinical empowerment, equipment quality control, and digital services, using digital intelligence to assist hospitals in delivering more convenient medical services. Care delivered by equipment extends to people, creating boundaryless medical care.

More precise and smarter innovative products and solutions are playing an increasingly important role in clinical diagnosis and treatment in China. More of GE Healthcare's current and future innovations will be developed by the China R&D team in collaboration with global resources, which is an inevitable result of the deepening advancement of GE Healthcare’s China strategy. The grand occasion of the 6th CIIE has also given GE Healthcare greater confidence to continue pushing forward the implementation of 'boundaryless innovation' in the field of medical imaging, exploring high-end medical devices produced in China to advance towards even more cutting-edge technological levels, promoting the upgrading of high-end medical device manufacturing in China, and continuously exporting Chinese wisdom to the world for win-win cooperation!